What Your Bloodwork Isn't Telling You About Your Health

Your Labs Say "Normal." So Why Do You Feel This Way?

You have your annual results in hand. Everything is flagged green. Yet you are exhausted, your hair is thinning, your periods shifted, or your weight is creeping up despite no change in diet. You are not imagining it. Standard lab panels were built around reference ranges derived predominantly from male or non-sex-stratified cohorts, and many thresholds were set decades before researchers understood how profoundly menstrual cycle phase, hormonal status, pregnancy, and menopause alter physiology and lab interpretation.

A 2021 analysis in JAMA Network Open found that women wait significantly longer than men for diagnoses across a broad range of conditions, a gap researchers partly attributed to over-reliance on population-level reference intervals that do not account for sex-specific biology. This is not a small rounding error. It can mean years of symptoms before anyone connects the dots.

The sections below walk through the most clinically significant gaps, organized by what the standard panel checks, what it misses, and what you can ask your provider to add.

The Thyroid Panel Gap: TSH Is a Starting Point, Not a Complete Picture

A normal TSH does not mean your thyroid is working well for you. TSH measures the pituitary's signal to the thyroid, not what thyroid hormone is actually doing inside your cells. For many women, especially those with Hashimoto's thyroiditis, perimenopause-related hormonal shifts, or high oral estrogen exposure, the TSH can sit within the "normal" range while free T3 and free T4 tell a very different story.

Why Women Are Disproportionately Affected

Hashimoto's thyroiditis affects women 7 to 10 times more often than men, making it the single most common cause of hypothyroidism in iodine-sufficient countries. The antibody load, specifically thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies (TgAb), can be elevated and damaging for years before TSH drifts out of range. Standard panels do not include these antibodies unless specifically ordered.

Oral estrogen (from combined contraceptives or menopausal hormone therapy taken by mouth) raises thyroid-binding globulin, which reduces the free fraction of circulating thyroid hormone. If you start oral estrogen and your TSH creeps up, it is not necessarily disease progression. It may require a dose adjustment or a switch to transdermal estrogen, which does not significantly affect thyroid-binding globulin.

What to Ask For

• Free T4 (FT4) and free T3 (FT3), not just total T4
• TPO antibodies and TgAb, especially if you have fatigue, cold intolerance, hair loss, or a family history of autoimmune disease
• Reverse T3 (rT3) if you have high physiologic stress, caloric restriction, or recent illness, since these can push T4 into inactive reverse T3 rather than active T3

Pregnancy and the First-Trimester TSH Shift

If you are pregnant or trying to conceive, the standard TSH reference range does not apply to you. The American Thyroid Association recommends trimester-specific TSH targets, with a first-trimester upper limit closer to 2.5 mIU/L rather than the population cutoff of 4.0 to 4.5 mIU/L used in most labs. An untreated or undertreated TSH between 2.5 and 4.0 mIU/L in the first trimester has been associated with increased risk of pregnancy loss and impaired fetal neurodevelopment. Your OB or reproductive endocrinologist should be ordering a TSH specific to pregnancy, not using your pre-pregnancy threshold.

Iron Deficiency Without Anemia: The Most Commonly Missed Diagnosis in Reproductive-Age Women

This is one of the most underappreciated gaps in routine women's health labs. A complete blood count (CBC) can be entirely normal while your ferritin, the stored iron marker, sits at a level too low to support normal energy metabolism, hair growth, or cognitive function.

A study in the British Journal of Haematology found that symptoms of iron deficiency, including fatigue, poor concentration, and hair shedding, appear at ferritin levels well below 30 micrograms per liter, even when hemoglobin remains normal. Many labs flag ferritin as low only below 12 or 15 micrograms per liter, a threshold set to detect frank deficiency rather than functional sufficiency.

Life-Stage Considerations

Reproductive years. Monthly menstrual blood loss, especially with heavy periods from fibroids, endometriosis, or an IUD, makes iron deficiency without anemia extremely common. The American College of Obstetricians and Gynecologists defines heavy menstrual bleeding as more than 80 mL per cycle and recommends screening ferritin, not just CBC, in women with heavy flow.

Pregnancy. Iron requirements roughly double during pregnancy. The CDC recommends all pregnant women receive iron supplementation, and serum ferritin below 30 micrograms per liter in pregnancy warrants treatment even when hemoglobin looks acceptable.

Perimenopause and beyond. Irregular, sometimes very heavy perimenopausal periods can deplete stores just as menstrual cycles become unpredictable. Once periods stop entirely, absorption becomes the main variable, and ferritin can recover, but many postmenopausal women entering that transition carried a deficit they never addressed.

What to Ask For

Ask for serum ferritin specifically. Aim for a level above 50 to 70 micrograms per liter for symptom resolution in most women, though some experts in female pattern hair loss use a target closer to 70 to 100 micrograms per liter. A standard CBC alone will not tell you this.

Insulin Resistance: The Years Before Prediabetes Appears on Paper

Fasting glucose and even a hemoglobin A1c can be completely normal while insulin resistance is already driving weight gain, irregular periods, acne, and inflammation. This gap is particularly consequential for women with PCOS.

Up to 70% of women with PCOS have insulin resistance, yet a fasting glucose alone misses approximately 50% of cases because these women are still secreting enough compensatory insulin to keep glucose within range. The lab result looks fine. The metabolic machinery is already under strain.

The Tests Standard Panels Skip

A fasting insulin level, calculated alongside fasting glucose as the HOMA-IR index (Homeostatic Model Assessment of Insulin Resistance), gives a far earlier and more actionable picture. A HOMA-IR above 2.0 is considered elevated in most clinical frameworks, with some PCOS-specific guidelines using a cutoff of 2.5. HOMA-IR calculation and interpretation are described in detail in the original 1985 validation paper and have since been applied broadly in women's metabolic research.

A two-hour oral glucose tolerance test (OGTT) with insulin levels at fasting, one hour, and two hours gives even more granular information about how your pancreas responds to a carbohydrate load. This is the test most reproductive endocrinologists use when evaluating PCOS-associated metabolic risk.

Life-Stage Notes

Trying to conceive. Insulin resistance impairs ovulation and egg quality. Metformin is sometimes prescribed off-label in PCOS to improve insulin sensitivity before or during ovulation induction, a use discussed in ASRM's PCOS clinical guidance.

Perimenopause. Estrogen has a protective effect on insulin sensitivity. As estrogen declines in perimenopause, insulin resistance can worsen rapidly even in women who never had PCOS. Waist circumference, fasting insulin, and triglycerides tell more of this story than fasting glucose alone.

Postmenopause. Menopausal hormone therapy, particularly estradiol, has been shown in the SWAN study cohort to attenuate the worsening of insulin resistance that typically accompanies the menopausal transition. This is a nuanced hormonal interaction that routine glucose testing will not illuminate.

Hormonal Status in Perimenopause: Why a Single Lab Draw Misleads

One of the most frustrating experiences in perimenopause care is being told your FSH or estradiol is "normal" and therefore you cannot be perimenopausal. A single snapshot of these hormones is almost clinically meaningless during the transition.

FSH and estradiol fluctuate enormously cycle to cycle and even day to day during perimenopause. The STRAW+10 staging system, published by The Menopause Society, defines perimenopause by symptom patterns and menstrual cycle changes, not by any single hormone level. An FSH drawn on day 3 of one cycle may be 18. The same woman three weeks later may have an FSH of 52.

What the Standard Metabolic Panel Also Misses in Midlife

As estrogen declines, low-density lipoprotein (LDL) cholesterol often rises and high-density lipoprotein (HDL) can fall, changing cardiovascular risk in ways a standard lipid panel captures partially but without context. A standard panel will not flag that this LDL rise is new, postmenopausal, and potentially responsive to estrogen therapy rather than statins as a first intervention. The American Heart Association's 2020 statement on cardiovascular risk in women specifically identifies menopause as an independent risk-accelerating event that requires sex-specific cardiovascular risk assessment.

Anti-Müllerian hormone (AMH) is another marker not included in standard panels. AMH reflects ovarian reserve and tracks the pace of reproductive aging. While it is most commonly ordered for fertility evaluation, it also provides useful context in perimenopause, helping to differentiate early menopause from other causes of cycle irregularity.

Autoimmune Markers: The Missing Piece in Unexplained Symptoms

Women develop autoimmune conditions at roughly 4 times the rate of men, yet autoimmune screening is rarely part of a routine panel. A basic metabolic panel and CBC give no information about antinuclear antibodies (ANA), anti-double-stranded DNA, anti-Smith, or anti-SSA/SSB antibodies relevant to lupus and Sjögren's syndrome, conditions that frequently present in women of reproductive age or in perimenopause.

Many women spend years with fatigue, joint pain, dry eyes, or cycle irregularities before anyone orders an ANA screen. A positive ANA alone is not diagnostic. It is a reason to look further. Skipping it guarantees the conversation never starts.

Postpartum Thyroiditis: A Commonly Missed Autoimmune Event

Postpartum thyroiditis affects approximately 5 to 10% of women in the first year after delivery. It typically presents as a transient hyperthyroid phase (weeks 1 to 4 postpartum) followed by a hypothyroid phase (months 4 to 8), with most women recovering fully by 12 months. A minority, roughly 20 to 30%, go on to develop permanent hypothyroidism.

Standard postpartum care does not routinely include thyroid function testing unless a woman reports symptoms. Because postpartum fatigue and mood changes are expected and normalized, the thyroid component is easily missed. If you are postpartum and experiencing unusual fatigue, palpitations, mood shifts, or weight changes beyond what you would expect, ask specifically for a TSH with free T4, and ask whether TPO antibodies were checked during pregnancy.

Vitamin D and Magnesium: The Two Deficiencies Labs Often Check Incompletely

Vitamin D is now commonly included in annual panels, which is progress. The problem is the threshold. Many labs flag insufficiency only below 20 ng/mL (50 nmol/L). A growing body of evidence, including data from the VITAL trial, suggests that levels between 20 and 30 ng/mL are functionally suboptimal for bone health, immune function, and mood regulation in many women. Women with darker skin pigmentation, limited sun exposure, obesity (where vitamin D is sequestered in adipose tissue), or malabsorption disorders are at highest risk and most likely to be in this borderline zone that labs do not flag.

Magnesium is almost never ordered in routine panels despite the fact that 48% of Americans consume less than the recommended daily amount, with women particularly affected given higher relative needs during pregnancy and lactation. Serum magnesium is a poor marker of total body stores because the body tightly defends serum levels at the expense of cellular and bone magnesium. Red blood cell magnesium is a better functional marker and worth requesting if you have unexplained muscle cramping, migraines, poor sleep, or PMS that is disproportionately severe.

The WomanRx Life-Stage Lab Checklist: What to Ask For Beyond the Basics

This framework is not a substitute for individualized clinical assessment. It is a starting point for the conversation with your provider.

Reproductive years (ages 18 to 40, not pregnant):

• Ferritin (not just CBC), especially with heavy periods
• Fasting insulin and HOMA-IR if you have PCOS, acne, irregular cycles, or difficulty with weight
• TPO antibodies if you have fatigue, hair loss, cold intolerance, or family history of thyroid disease
• Free T3 and free T4 alongside TSH
• 25-hydroxyvitamin D with a target of 40 to 60 ng/mL for most women
• ANA screen if you have unexplained joint pain, rashes, or fatigue

Trying to conceive:

• AMH to assess ovarian reserve
• TSH with trimester-specific targets (first-trimester goal: <2.5 mIU/L)
• Fasting insulin and two-hour OGTT if PCOS is present or suspected
• Ferritin with target above 30 micrograms per liter before conception

Pregnancy:

• TSH each trimester with pregnancy-specific reference ranges
• Ferritin at first prenatal visit and again at 24 to 28 weeks
• One-hour glucose challenge at 24 to 28 weeks (three-hour OGTT if abnormal)

Postpartum:

• TSH with free T4 at 6 to 8 weeks postpartum if symptomatic, or at 3 to 6 months if you were TPO-antibody positive during pregnancy

Perimenopause (typically ages 40 to 55):

• FSH and estradiol interpreted in context of cycle day and symptoms, not as single snapshot
• Fasting insulin alongside fasting glucose as metabolic risk shifts
• Full lipid panel with LDL, HDL, triglycerides, and non-HDL cholesterol
• AMH if timing of menopause is clinically relevant
• Ferritin if periods are becoming heavier or more irregular

Postmenopause:

• DEXA scan for bone mineral density (USPSTF recommends starting at age 65, earlier with risk factors)
• Full thyroid panel including free T4 and TPO-Ab if symptomatic
• Fasting lipids at least every 5 years, more frequently with abnormal results or statin use

What the Evidence Gap Means for You Specifically

Women have been systematically under-represented in the clinical trials that defined normal reference ranges and treatment thresholds. The NIH Revitalization Act of 1993 required the inclusion of women in federally funded research, but the effects took years to reach clinical laboratory standards. Many of the reference intervals your lab uses today were derived from studies conducted before that mandate, or from datasets where women made up a minority of subjects.

This is not speculation. A 2020 analysis in Biology of Sex Differences found that sex-disaggregated reporting remained the exception rather than the rule in biomedical research even decades after the 1993 mandate. For you, this means that a result labeled "normal" may be normal for a reference population that does not reflect your sex, your hormonal status, your reproductive stage, or your ethnicity.

Knowing this does not mean distrusting every lab result. It means understanding what a result can and cannot tell you, asking what reference population the range was derived from, and being willing to push for additional testing when your symptoms and your labs do not match.

Who Benefits Most from an Extended Lab Panel

Not every woman needs every test listed here. The women most likely to gain actionable information from going beyond the basic panel include:

• Women with symptoms that do not have an obvious explanation: unexplained fatigue, hair thinning, weight changes, cognitive fog, mood shifts, or cycle irregularities
• Women with a first-degree relative with autoimmune thyroid disease, lupus, type 1 diabetes, or rheumatoid arthritis
• Women with PCOS or a history of gestational diabetes
• Women in perimenopause who are being told they are "not menopausal yet" based on a single hormone draw
• Women who are pregnant or planning pregnancy, particularly with a history of thyroid disease or miscarriage
• Women postpartum who are TPO-antibody positive or who had thyroid disease before conception
• Women of color, who are at higher risk of autoimmune conditions, vitamin D insufficiency, and metabolic disease, and who face well-documented disparities in time to diagnosis

As WomanRx medical reviewer Dr. Maya Okafor, MD, puts it: "A normal TSH and a normal CBC can both be true and still leave a woman's actual problem completely unaddressed. The standard panel is a screening net with large holes. Our job is to know where the holes are and order accordingly."

A Note on Direct-to-Consumer Lab Testing

Companies now offer women the option to order many of these tests without a provider order. This can be genuinely useful for filling gaps, but it comes with important caveats. A ferritin result or a fasting insulin level without clinical context and a follow-up conversation about what to do with the number can lead to unnecessary supplementation, unnecessary anxiety, or missed nuance. Use direct-to-consumer testing to start a conversation with your provider, not to replace one.